Thomas Holbro
Impact in
- Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
-
- Complement system in diseases 5
- Toxin Mechanisms and Immunotoxins 2
- Oncology 6
- HER2/EGFR in Cancer Research 6
- Co-authors
- Nancy E. Hynes (7 shared papers)Magdalena Koziczak (2 shared papers)Francisca Maurer (1 shared paper)Roger R. Beerli (1 shared paper)Carlos F. Barbas (1 shared paper)Gianluca Civenni (3 shared papers)Richard M. Neve (1 shared paper)Gema Alonso (1 shared paper)
- Journals
- Frontiers in Immunology (4 papers)Oncogene (2 papers)EMBO Reports (2 papers)The Annual Review of Pharmacology and Toxicology (1 paper)European Journal of Heart Failure (1 paper)
- Partner nations
- SwitzerlandUnited StatesUnited Kingdom
In The Last Decade
Thomas Holbro
18 papers receiving 2.3k citations
Thomas Holbro's Hit Papers
Peers
Comparison fields: 5 of 100
- Oncology 1.2k
- Radiology, Nuclear Medicine and Imaging 601
- Immunology and Allergy 115
- Molecular Biology 1.2k
- Cancer Research 196
Countries citing papers authored by Thomas Holbro
This map shows the geographic impact of Thomas Holbro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Holbro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Holbro more than expected).
Fields of papers citing papers by Thomas Holbro
This network shows the impact of papers produced by Thomas Holbro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Holbro. The network helps show where Thomas Holbro may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Holbro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation Hit paper breakdown → | 2003 | 803 |
| 2 | ErbB Receptors: Directing Key Signaling Networks Throughout Life Hit paper breakdown → | 2004 | 521 |
| 3 | The ErbB receptors and their role in cancer progression Hit paper breakdown → | 2003 | 518 |
| 4 | 2004 | 137 | |
| 5 | 2003 | 113 | |
| 6 | 2002 | 96 | |
| 7 | 2001 | 44 | |
| 8 | 2020 | 26 | |
| 9 | 2003 | 25 | |
| 10 | 2021 | 23 | |
| 11 | 2016 | 22 | |
| 12 | 2021 | 20 | |
| 13 | 2022 | 9 | |
| 14 | 2021 | 8 | |
| 15 | 2023 | 8 | |
| 16 | 2020 | 5 | |
| 17 | 2022 | 2 | |
| 18 | 2003 | 1 |
About Thomas Holbro
Thomas Holbro is a scholar working on Immunology, Oncology, Molecular Biology, Cardiology and Cardiovascular Medicine and Epidemiology, having authored 18 papers that have together received 2.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (6 papers), Complement system in diseases (5 papers), Bacterial Infections and Vaccines (4 papers), Pneumonia and Respiratory Infections (4 papers), Heart Failure Treatment and Management (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Toxin Mechanisms and Immunotoxins (2 papers) and RNA and protein synthesis mechanisms (1 paper). The work is most often cited by research in Oncology (1.2k citations), Radiology, Nuclear Medicine and Imaging (601 citations), Immunology and Allergy (115 citations), Molecular Biology (1.2k citations) and Cancer Research (196 citations). Thomas Holbro has collaborated with scholars based in Switzerland, United States and United Kingdom. Frequent co-authors include Nancy E. Hynes, Magdalena Koziczak, Francisca Maurer, Roger R. Beerli, Carlos F. Barbas, Gianluca Civenni, Richard M. Neve, Gema Alonso, Laura Lin and Max M. Burger. Their work appears in journals such as Frontiers in Immunology, Oncogene, EMBO Reports, The Annual Review of Pharmacology and Toxicology and European Journal of Heart Failure.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.